<DOC>
	<DOCNO>NCT00604500</DOCNO>
	<brief_summary>This open-label , multiple-dose , study mometasone furoate/formoterol fumarate ( MF/F ) meter dose inhaler ( MDI ) 100/10 microgram ( mcg ) twice daily ( BID ) ( 2 puff MF/F MDI 50/5 mcg , administer twice day approximately 12 hour apart ) participants 12 year age old , diagnosis persistent asthma chronic obstructive pulmonary disease ( COPD ) least 12 month . The primary purpose study evaluate performance MF/F MDI integrate dose counter normal patient handling condition .</brief_summary>
	<brief_title>A Patient Handling Study Mometasone Furoate/Formortoral Fumarate ( MF/F ) Metered Dose Inhaler ( MDI ) With Integrated Dose Counter Adolescent Adult Subjects With Asthma Chronic Obstructive Pulmonary Disease ( Study P04703AM1 )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Diagnosis Criteria Inclusion : A participant must least 12 year age , either sex , race , diagnosis persistent asthma COPD least 12 month . A participant must able demonstrate correct use MDI without counter Screening Visit . A participant must demonstrate least 90 % compliance completion ediary , use counterstrip , use study medication 2week Screening Period . Participants serious uncontrolled medical disorder , judgment investigator , could interfere study , require treatment might interfere study . Participants judgment investigator and/or sponsor significant recent current , repetitive strain injury ( RSI ) may impact ability effectively participate full duration study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>